Entresto, a combination of an old drug valsartan with a novel neprilysin inhibitor sacubitril from Novartis, which was approved in July for treating heart failure, has been ear-marked by analysts as a ...
July 16 (Reuters) - A U.S. federal judge rejected Swiss drugmaker Novartis' (NOVN.S), opens new tab request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic version of ...
Novartis is already suing a long list of generics producers that aim to bring copycats of the company's popular heart failure drug Entresto to market. Now, the Swiss pharma itself has become target in ...
As blockbuster heart failure drug Entresto inches toward a patent cliff, Novartis is calling on the FDA—again—to keep early-bird generics at bay. At the time, Novartis argued greenlighting any generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback